HDX-MS study on garadacimab binding to activated FXII reveals potential binding interfaces through differential solvent exposure

Saw Yen OwResearch and Development, CSL Limited, Bio21 Molecular Science and Biotechnology Institute, Parkville, AustraliaView further author information

Eugene A. KappResearch and Development, CSL Limited, Bio21 Molecular Science and Biotechnology Institute, Parkville, AustraliaView further author information

Vesna TomasetigResearch and Development, CSL Limited, Bio21 Molecular Science and Biotechnology Institute, Parkville, AustraliaView further author information

Anton ZalewskiResearch and Development, CSL Limited, Bio21 Molecular Science and Biotechnology Institute, Parkville, AustraliaView further author information

Jason SimmondsResearch and Development, CSL Limited, Bio21 Molecular Science and Biotechnology Institute, Parkville, AustraliaView further author information

Con PanousisResearch and Development, CSL Limited, Bio21 Molecular Science and Biotechnology Institute, Parkville, AustraliaView further author information

Michael J. WilsonResearch and Development, CSL Limited, Bio21 Molecular Science and Biotechnology Institute, Parkville, AustraliaView further author information

Andrew D. NashResearch and Development, CSL Limited, Bio21 Molecular Science and Biotechnology Institute, Parkville, AustraliaView further author information

Matthias PelzingResearch and Development, CSL Limited, Bio21 Molecular Science and Biotechnology Institute, Parkville, AustraliaCorrespondence[email protected]
View further author information

Your download is now in progress and you may close this window